False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients

Multiple Sclerosis

Volumn 22, Issue 9, 2016, Pages 1231-1234

  Cohen, Mikael ^a   De Sèze, JéRome ^b   Marignier, Romain ^c   Lebrun, Christine ^a  

^a PASTEUR HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

Multiple sclerosis; natalizumab; neuromyelitis optica

Indexed keywords

AQUAPORIN 4 ANTIBODY; BETA1A INTERFERON; METHYLPREDNISOLONE; NATALIZUMAB; OLIGOCLONAL BAND; RITUXIMAB; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; GADOLINIUM; IMMUNOGLOBULIN G;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DEMYELINATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FALSE POSITIVE RESULT; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAPLEGIA; RELAPSE; YOUNG ADULT; AUTOIMMUNITY; BLOOD; IMMUNOLOGY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SEROLOGY; TIME FACTOR; TREATMENT OUTCOME; CEREBROSPINAL FLUID ANALYSIS; DIFFERENTIAL DIAGNOSIS; GENERAL CONDITION DETERIORATION; NEUROLOGIC EXAMINATION;

ADULT; AQUAPORIN 4; AUTOANTIBODIES; AUTOIMMUNITY; BIOMARKERS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE SCLEROSIS; NATALIZUMAB; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEROLOGIC TESTS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84979587290     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516630823     Document Type: Article

References (6)

1. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 1-14.
2. Wang K-C, Lin K-H, Lee T-C, et al. Poor responses to interferon-beta treatment in patients with neuromyelitis optica and multiple sclerosis with long spinal cord lesions. Kira J-I,. ed. PLoS ONE 2014; 9 (6): e98192.
3. Kleiter I,. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69 (2): 239-245.
4. Kitley J, Evangelou N, Küker W, et al. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci 2014; 1-3.
5. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 58 (6): 840-846.
6. Sánchez Gomar I, Díaz-Sánchez M, Uclés Sánchez AJ, et al. An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab. BMC Neurol 2014; 14 (1): 139.